SCHEMBL5212458

SCHEMBL5212458

COC(C)(C)CNC(=O)c1cnc(Nc2cccc(Cl)c2)cc1C(F)(F)F

nearest known ligand 0.65

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 19/20 0.65
POLB P06746 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5213603 0.88 CNR2 (0.66) CNR2POLB
SCHEMBL5212532 0.85 CNR2 (0.63) CNR2POLB
SCHEMBL5213789 0.83 CNR2 (0.73) CNR2POLB
SCHEMBL5078865 0.83 CNR2 (0.61) CNR2POLB
SCHEMBL5213958 0.83 CNR2 (0.67) CNR2POLB
SCHEMBL5077144 0.82 CNR2 (0.81) CNR2POLB
SCHEMBL5214258 0.81 CNR2 (0.91) CNR2
SCHEMBL5459863 0.80 CNR2 (0.81) CNR2POLB
SCHEMBL5457359 0.80 CNR2 (0.67) CNR2POLB
SCHEMBL5077106 0.80 CNR2 (0.66) CNR2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1565442-B1 PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS GLAXO GROUP LTD (GB) 2007-11-14 EP claimed
EP-1565442-B1 PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS GLAXO GROUP LTD (GB) 2007-11-14 EP disclosed
US-20060240048-A1 Pyridine derivatives as cb2 receptor modulators GLAXO GROUP LIMITED (GB) 2006-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060240048-A1 Pyridine derivatives as cb2 receptor modulators CNR2, CNR1, TRPV1 CNR2 1/4885POLB 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.